pds
biotechnology
present
results
phase
trial
phase
clinical
strategy
patients
advanced
malignancies
florham
park
globe
newswire
pds
biotechnology
corporation
pds
biotech
company
nasdaq
pdsb
immunotherapy
company
developing
novel
cancer
therapies
infectious
disease
vaccines
based
company
proprietary
activating
technology
today
announced
chief
medical
officer
lauren
wood
present
key
data
company
previously
reported
phase
trial
planned
phase
clinical
studies
patients
advanced
malignancies
world
vaccine
congress
held
virtually
september
october
abstract
plus
peptides
treatment
cancers
session
cancer
immunotherapy
viral
associated
cancers
date
wednesday
september
time
et
pds
biotechnology
pds
biotech
immunotherapy
company
growing
pipeline
cancer
immunotherapies
infectious
disease
vaccines
based
company
proprietary
activating
technology
platform
effectively
delivers
antigens
vivo
uptake
processing
also
activating
critical
type
interferon
immunological
pathway
resulting
production
potent
killer
well
neutralizing
antibodies
pds
biotech
engineered
multiple
therapies
based
combinations
antigens
designed
train
immune
system
better
recognize
disease
cells
effectively
attack
destroy
forward
looking
statements
press
release
includes
statements
within
meaning
private
securities
litigation
reform
act
current
expectations
projections
future
events
cases
statements
identified
terminology
may
potential
continue
expects
anticipates
intends
plans
believes
estimates
similar
expressions
statements
based
upon
current
beliefs
expectations
assumptions
include
statements
regarding
proposed
public
offering
anticipated
closing
statements
subject
number
risks
uncertainties
many
difficult
predict
including
market
conditions
whether
proposed
offering
completed
satisfaction
customary
closing
conditions
related
proposed
offering
factors
described
pds
biotech
filings
sec
information
release
provided
date
release
pds
biotech
undertakes
obligation
update
statements
contained
release
based
new
information
future
events
otherwise
except
required
law
media
investor
relations
contact
deanne
randolph
pds
biotechnology
phone
email
drandolph
james
salierno
ruth
group
phone
email
jsalierno
